CSIMarket
 


Accustem Sciences Inc   (ACUT)
Other Ticker:  
 

Cumulative Accustem Sciences Inc 's Working Capital Ratio for Trailing Twelve Months Period

ACUT's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ACUT Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter


Y / Y Current Liabilities Growth - - - - -
Y / Y Current Assets Growth - - - - -
Working Capital Ratio for Trailing Twelve Months Period 3.42 4.35 5.78 - -
Total Ranking # # # # #
Seq. Current Liabilities Growth 12.78 % 30.35 % - - -
Seq. Current Assets Growth -31.97 % -26.88 % - - -


Working Capital Ratio for Trailing Twelve Months Period Comment
On the trailing twelve months basis Due to increase in Current Liabilities in the III. Quarter to $1 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 3.42 above Accustem Sciences Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry Accustem Sciences Inc achieved highest Working Capital Ratio for Trailing Twelve Months Period. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about ACUT
Working Capital Ratio ACUT in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry #
Sector #
S&P 500 # 0


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
0 0 0
 




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Galecto Inc   9.38 
Xilio Therapeutics inc   9.29 
Phathom Pharmaceuticals Inc   9.26 
Renovorx Inc   9.21 
Iterum Therapeutics Plc  9.17 
Reviva Pharmaceuticals Holdings Inc   9.12 
Processa Pharmaceuticals Inc   8.99 
Evoke Pharma Inc   8.95 
Regulus Therapeutics Inc.  8.82 
Zentalis Pharmaceuticals Inc   8.78 
Allakos Inc   8.75 
Immunic Inc   8.73 
Tango Therapeutics Inc   8.73 
Clearside Biomedical Inc   8.66 
Matinas Biopharma Holdings Inc   8.64 
Alzamend Neuro Inc   8.42 
Geovax Labs Inc   8.36 
Chimerix inc   8.34 
Enveric Biosciences Inc.  8.33 
Bolt Biotherapeutics Inc   8.32 
Ionis Pharmaceuticals Inc.  8.18 
Bright Minds Biosciences Inc   8.11 
Rain Therapeutics inc   8.09 
Leap Therapeutics inc   8.08 
Sio Gene Therapies Inc   8.07 
Cara Therapeutics inc   7.95 
Siga Technologies Inc  7.94 
Virpax Pharmaceuticals Inc   7.93 
Assembly Biosciences Inc   7.87 
Zai Lab Limited  7.85 


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

NVS's Profile

Stock Price

NVS's Financials

Business Description

Fundamentals

Charts & Quotes

NVS's News

Suppliers

NVS's Competitors

Customers & Markets

Economic Indicators

NVS's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071